Bayer’s stock has not been a source of good humor for a long time, primarily thanks to Monsanto, while the company’s pharmaceuticals division has once again released two good pieces of news. The detailed results of the phase III study for finerenone were presented at a meeting of the American Society of Nephrology. The active ingredient is the first member of its class of substances “that has shown benefits in terms of renal and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes,” said Bayer. In addition, the substance has shown good tolerance.
Bayer plans to apply for approval of finerenone in an indication for patients with chronic kidney disease and type 2 diabetes before the end of the year.
“Despite existing treatment options that focus on hemodynamic and metabolic signaling pathways, patients with chronic kidney disease and type 2 diabetes have a residual risk of their kidney disease getting worse. The findings from FIDELIO-DKD provide important data that suggests a potential new strategy for treating these patients, ”said Professor George L. Bakris, MD, Department of Medicine, American Heart Association Comprehensive Hypertension Center, University of Chicago Medicine, USA, and lead author of the FIDELIO-DKD study.
FoundationOneCDx has already gone one step further: The US drug agency approved this test for Vitrakvi (larotrectinib) as an accompanying diagnostic test to support the identification of NTRK fusion-positive patients.
“Vitrakvi has proven clinical efficacy and is the first approved treatment specifically developed for patients with TRK fusion tumor,” said Robert LaCaze, member of the Executive Committee of Bayer’s Pharmaceuticals Division and head of the Oncology Strategic Business Unit at Bayer. “With FoundationOne®CDx approved in the United States for Vitrakvi, patients who can benefit from this treatment can be more accurately identified,” said the manager.
Bayer’s share ended XETRA trading on Friday at EUR 42.425. It was only on Thursday that the DAX had hit a new multi-year low at EUR 41.51 and is thus still below the Corona crash low from May at EUR 44.855.
At a glance – chart and news: Bayer